KIR3DL1 and acute lymphoblastic leukemia: While much of the benefits of NK cell alloreactivity are reported for myeloid indications, a pediatric study of 85 patients undergoing TCD haplo-HCT showed that patients transplanted for ALL from a KIR B-haplotype donor had a significantly better EFS than those with KIR haplotype A donors.